237 related articles for article (PubMed ID: 24731673)
1. Heritability of variation in glycaemic response to metformin: a genome-wide complex trait analysis.
Zhou K; Donnelly L; Yang J; Li M; Deshmukh H; Van Zuydam N; Ahlqvist E; ; Spencer CC; Groop L; Morris AD; Colhoun HM; Sham PC; McCarthy MI; Palmer CN; Pearson ER
Lancet Diabetes Endocrinol; 2014 Jun; 2(6):481-7. PubMed ID: 24731673
[TBL] [Abstract][Full Text] [Related]
2. Genome-wide association analysis identifies ancestry-specific genetic variation associated with acute response to metformin and glipizide in SUGAR-MGH.
Li JH; Brenner LN; Kaur V; Figueroa K; Schroeder P; Huerta-Chagoya A; ; ; Udler MS; Leong A; Mercader JM; Florez JC
Diabetologia; 2023 Jul; 66(7):1260-1272. PubMed ID: 37233759
[TBL] [Abstract][Full Text] [Related]
3. Variation in the glucose transporter gene SLC2A2 is associated with glycemic response to metformin.
Zhou K; Yee SW; Seiser EL; van Leeuwen N; Tavendale R; Bennett AJ; Groves CJ; Coleman RL; van der Heijden AA; Beulens JW; de Keyser CE; Zaharenko L; Rotroff DM; Out M; Jablonski KA; Chen L; Javorský M; Židzik J; Levin AM; Williams LK; Dujic T; Semiz S; Kubo M; Chien HC; Maeda S; Witte JS; Wu L; Tkáč I; Kooy A; van Schaik RHN; Stehouwer CDA; Logie L; ; ; ; Sutherland C; Klovins J; Pirags V; Hofman A; Stricker BH; Motsinger-Reif AA; Wagner MJ; Innocenti F; 't Hart LM; Holman RR; McCarthy MI; Hedderson MM; Palmer CNA; Florez JC; Giacomini KM; Pearson ER
Nat Genet; 2016 Sep; 48(9):1055-1059. PubMed ID: 27500523
[TBL] [Abstract][Full Text] [Related]
4. Genome-Wide Meta-analysis Identifies Genetic Variants Associated With Glycemic Response to Sulfonylureas.
Dawed AY; Yee SW; Zhou K; van Leeuwen N; Zhang Y; Siddiqui MK; Etheridge A; Innocenti F; Xu F; Li JH; Beulens JW; van der Heijden AA; Slieker RC; Chang YC; Mercader JM; Kaur V; Witte JS; Lee MTM; Kamatani Y; Momozawa Y; Kubo M; Palmer CNA; Florez JC; Hedderson MM; 't Hart LM; Giacomini KM; Pearson ER; ;
Diabetes Care; 2021 Dec; 44(12):2673-2682. PubMed ID: 34607834
[TBL] [Abstract][Full Text] [Related]
5. Different clinical prognostic factors are associated with improved glycaemic control: findings from MARCH randomized trial.
Han J; Yu H; Tu Y; Pang J; Liu F; Bao Y; Yang W; Jia W
Diabet Med; 2017 Apr; 34(4):490-499. PubMed ID: 27151271
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenomics of GLP-1 receptor agonists: a genome-wide analysis of observational data and large randomised controlled trials.
Dawed AY; Mari A; Brown A; McDonald TJ; Li L; Wang S; Hong MG; Sharma S; Robertson NR; Mahajan A; Wang X; Walker M; Gough S; Hart LM'; Zhou K; Forgie I; Ruetten H; Pavo I; Bhatnagar P; Jones AG; Pearson ER;
Lancet Diabetes Endocrinol; 2023 Jan; 11(1):33-41. PubMed ID: 36528349
[TBL] [Abstract][Full Text] [Related]
7. Glycaemic control among patients with type 2 diabetes mellitus in seven European countries: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) study.
Alvarez Guisasola F; Mavros P; Nocea G; Alemao E; Alexander CM; Yin D
Diabetes Obes Metab; 2008 Jun; 10 Suppl 1():8-15. PubMed ID: 18435669
[TBL] [Abstract][Full Text] [Related]
8. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
9. Important differences in the durability of glycaemic response among second-line treatment options when added to metformin in type 2 diabetes: a retrospective cohort study.
Mamza J; Mehta R; Donnelly R; Idris I
Ann Med; 2016; 48(4):224-34. PubMed ID: 26982210
[TBL] [Abstract][Full Text] [Related]
10. The effect of obesity on glycaemic response to metformin or sulphonylureas in Type 2 diabetes.
Donnelly LA; Doney AS; Hattersley AT; Morris AD; Pearson ER
Diabet Med; 2006 Feb; 23(2):128-33. PubMed ID: 16433709
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety over 26 weeks of an oral treatment strategy including sitagliptin compared with an injectable treatment strategy with liraglutide in patients with type 2 diabetes mellitus inadequately controlled on metformin: a randomised clinical trial.
Charbonnel B; Steinberg H; Eymard E; Xu L; Thakkar P; Prabhu V; Davies MJ; Engel SS
Diabetologia; 2013 Jul; 56(7):1503-11. PubMed ID: 23604551
[TBL] [Abstract][Full Text] [Related]
12. Reduced-function SLC22A1 polymorphisms encoding organic cation transporter 1 and glycemic response to metformin: a GoDARTS study.
Zhou K; Donnelly LA; Kimber CH; Donnan PT; Doney AS; Leese G; Hattersley AT; McCarthy MI; Morris AD; Palmer CN; Pearson ER
Diabetes; 2009 Jun; 58(6):1434-9. PubMed ID: 19336679
[TBL] [Abstract][Full Text] [Related]
13. Early glycaemic control in metformin users receiving their first add-on therapy: a population-based study of 4,734 people with type 2 diabetes.
Thomsen RW; Baggesen LM; Søgaard M; Pedersen L; Nørrelund H; Buhl ES; Haase CL; Johnsen SP
Diabetologia; 2015 Oct; 58(10):2247-53. PubMed ID: 26277380
[TBL] [Abstract][Full Text] [Related]
14. Long-term sustainability of glycaemic achievements with second-line antidiabetic therapies in patients with type 2 diabetes: A real-world study.
Montvida O; Shaw JE; Blonde L; Paul SK
Diabetes Obes Metab; 2018 Jul; 20(7):1722-1731. PubMed ID: 29536608
[TBL] [Abstract][Full Text] [Related]
15. Sodium-glucose co-transporter-2 inhibitors, the latest residents on the block: Impact on glycaemic control at a general practice level in England.
Heald AH; Fryer AA; Anderson SG; Livingston M; Lunt M; Davies M; Moreno GYC; Gadsby R; Young RJ; Stedman M
Diabetes Obes Metab; 2018 Jul; 20(7):1659-1669. PubMed ID: 29516618
[TBL] [Abstract][Full Text] [Related]
16. A UK nationwide prospective study of treatment change in MODY: genetic subtype and clinical characteristics predict optimal glycaemic control after discontinuing insulin and metformin.
Shepherd MH; Shields BM; Hudson M; Pearson ER; Hyde C; Ellard S; Hattersley AT; Patel KA;
Diabetologia; 2018 Dec; 61(12):2520-2527. PubMed ID: 30229274
[TBL] [Abstract][Full Text] [Related]
17. Impact of glycemic traits, type 2 diabetes and metformin use on breast and prostate cancer risk: a Mendelian randomization study.
Au Yeung SL; Schooling CM
BMJ Open Diabetes Res Care; 2019; 7(1):e000872. PubMed ID: 31908803
[TBL] [Abstract][Full Text] [Related]
18. Durability of glycaemic control in patients with type 2 diabetes after metformin failure: Prognostic model derivation and validation using the DISCOVER study.
Ling S; Sun P; Zaccardi F; Khosla S; Cooper A; Fenici P; Khunti K
Diabetes Obes Metab; 2020 May; 22(5):828-837. PubMed ID: 31944528
[TBL] [Abstract][Full Text] [Related]
19. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial.
Frías JP; Guja C; Hardy E; Ahmed A; Dong F; Öhman P; Jabbour SA
Lancet Diabetes Endocrinol; 2016 Dec; 4(12):1004-1016. PubMed ID: 27651331
[TBL] [Abstract][Full Text] [Related]
20. Metformin in women with type 2 diabetes in pregnancy (MiTy): a multicentre, international, randomised, placebo-controlled trial.
Feig DS; Donovan LE; Zinman B; Sanchez JJ; Asztalos E; Ryan EA; Fantus IG; Hutton E; Armson AB; Lipscombe LL; Simmons D; Barrett JFR; Karanicolas PJ; Tobin S; McIntyre HD; Tian SY; Tomlinson G; Murphy KE;
Lancet Diabetes Endocrinol; 2020 Oct; 8(10):834-844. PubMed ID: 32946820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
